FDA Once More Delays Action on Pompe Disease Candidate

The FDA has issued a Deferred Action letter for Amicus Therapeutics’ biologic license application (BLA) for cipaglucosidase alfa, the biologic component of AT-GAA, its investigational dual therapy for muscle-wasting Pompe disease.
Source: Drug Industry Daily